ACW secures funding beyond XanaMIA AD trial final results
Filed with ASX · · 40 pages · English
Actinogen secures funding beyond XanaMIA Alzheimer’s disease trial topline final results in November following positive interim analysis outcome - share placement and share purchase plan to raise up to approximately $17.0 million Highlights: • Following the release of the positive result of its XanaMIA Alzheimer’s trial Interim Analysis on Friday, Actinogen has received firm commitments for a non-
Actinogen Medical Limited on 6ix
In the deck
Earlier from Actinogen Medical
- ACW December 2025 quarterly activity report & Appendix 4C
- Continuation of Trading Halt
- ACW positive XanaMIA Interim Analysis outcome
- Trading Halt
- Actinogen secures $4.3m of non-dilutive R&D tax funding
Later from Actinogen Medical
- Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
- ACW receives further $1.9m FY2025 R&D rebate from ATO
- Actinogen HY2025 financial report and Appendix 4D
- ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
- ACW successfully completes $16.8m Placement and SPP
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical